Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart in Combination with Antiangiogenesis Drugs and Neoadjuvant Chemotherapy for Locally Progressive Gastric Cancer / Gastroesophageal Junction Carcinoma
NCT06603974Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of benmelstobart in gastric cancer (GC) and gastroesophageal junction carcinoma (GEJ), sponsored by Xijing Hospital. Primary endpoint: Pathological complete response at 2 years. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
gastric cancer (GC)gastroesophageal junction carcinoma (GEJ)
Beyond the preview
Go deeper on NCT06603974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603974.